Patients with histologically or cytologically confirmed negative EGFR (including EGFR exon 19 deletion or L858R mutations) or ALK/ROS1-mutated locally advanced unresectable NSCLC were screened.

1. ≥18 years old with no restrictions on sex;

2. Peripheral tumor, or central lung cancer with non-squamous tissue or a mixed tissue with less than 50% squamous carcinoma;

3. Eastern cooperative oncology group (ECOG) score ≤2 was required;

4. Received systemic chemotherapy or combined chemotherapy and immumitherapy for ≥ 4 weeks without progression;

5. .No cavity inside the tumor, and located ≥ 1 cm of the main pulmonary artery trunk;

6. No symptoms of hemoptysis;

7. Adequate hepatic and renal functions with a negative urine protein;

8. Expected survival of more than 6 months.

Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT

What this study is about